Moderna, Inc. announced a major expansion of its USA manufacturing operations by bringing drug product manufacturing to its Moderna Technology Center (MTC) in Norwood, Massachusetts. With this onshoring move, the company will now manage complete end-to-end manufacturing for its mRNA medicines within the United States.

This development strengthens Moderna’s domestic production network, enhances supply resilience for both commercial and clinical products, and underscores its long-term commitment to USA-based manufacturing.

CEO Stéphane Bancel said the shift enables the company to complete “the full manufacturing loop under one roof,” adding that the expansion will also create new jobs in the community.

The investment supports Moderna’s broader goal of building a robust USA infrastructure capable of advancing its growing pipeline of mRNA vaccines and therapeutics. The company’s mRNA platform—recognized globally during its collaboration with the USA government in Operation Warp Speed—continues to enable innovation across infectious diseases, oncology, rare diseases and autoimmune conditions.

Construction of the new drug product facility at the Norwood site is underway, with completion targeted for the first half of 2027.